Biodesix reports Q3 EPS ($1.16), consensus ($1.51)

Reports Q3 revenue $21.77M, consensus $20.98M. “We delivered a strong third quarter with revenue growing 20% to $21.8 million and continued to improve our already strong gross margins to 81%, a 400-basis point increase year-over-year,” said Scott Hutton, CEO. “Our strategic expansion into primary care is proving to be additive, demonstrating our ability to drive adoption in pulmonology while also partnering with them to drive upstream testing in their referral network. Additionally, our Development Services business continues to accelerate with 97% year-over-year growth and another quarter ending with a record number of dollars under contract.”